Since their launch, CAR-T therapies have remained entrenched in uncertainties around their efficacy and safety. Over time, real-world data has aided in easing this uncertainty, which may drive significant changes in how CAR-T therapies are reimbursed. Join us at ISPOR, Europe to discuss how real-world data may drive the evolution of CAR-T reimbursement (19th November 2024, 3.15pm CET). #ISPOREurope #LifescienceDynamics #ISPOR #ISPOR2024 #pharma #biotech #CAR_T #Immunotherapy
Lifescience Dynamics Limited’s Post
More Relevant Posts
-
Dear #Linkedinfamily Stay informed with the latest updates! Catch our news bulletin for breaking news, in-depth analysis, and exclusive stories. Follow us to stay ahead and never miss out on important news. Centaur Pharma launches new generic cardiac drug ivabradine hydrochloride in US Click the Link Below for More & Detailed Info: https://lnkd.in/gmGBp-FQ Follow us for real-time updates and in-depth analysis. Lifescience Intellipedia Pvt. Ltd. Chemxpert Database #lifescienceintellipedia #lifesciences #chemxpert #chemxpertdatabase #database #daily #new #PharmaNews #PharmaUpdates #BiotechNews #PharmaInnovation #PharmaResearch #MedicalResearch #PharmaIndustry #NewMedication #PharmaTrends #Biopharma #PharmaTech
To view or add a comment, sign in
-
Dear #Linkedinfamily Stay informed with the latest updates! Catch our news bulletin for breaking news, in-depth analysis, and exclusive stories. Follow us to stay ahead and never miss out on important news. Centaur Pharma launches new generic cardiac drug ivabradine hydrochloride in US Click the Link Below for More & Detailed Info: https://lnkd.in/gmGBp-FQ Follow us for real-time updates and in-depth analysis. Lifescience Intellipedia Pvt. Ltd. Chemxpert Database #lifescienceintellipedia #lifesciences #chemxpert #chemxpertdatabase #database #daily #new #PharmaNews #PharmaUpdates #BiotechNews #PharmaInnovation #PharmaResearch #MedicalResearch #PharmaIndustry #NewMedication #PharmaTrends #Biopharma #PharmaTech
To view or add a comment, sign in
-
We all know the importance of Sample Management. Why not join #Avantor next week at our 4th EU Sample Management Symposium?! See below for more details and the links to register - see you there !! #Pharma #biotech #Avantorsetsscienceinmotion #SLAS2024
In the upcoming 4th EU Sample Management Symposium on June 20th in Frankfurt, Germany, industry experts will share key insights on the future of sample management. The morning session will be led by Dr. Patrick R. Merz (BASF), Orkun Ozhelvaci (BioNTech) and Neil Gow (UCB Pharma). The afternoon session will be presented by Xavier Briand and Dr. Luc Alexis Leuthold, both from Novartis. For more information on their talks and the Symposium, and to register, visit https://lnkd.in/ezNG6sv7. #SLAS2024 #SampleManagement #Biotech #Pharma
To view or add a comment, sign in
-
Looking forward presenting in 2 weeks, for the first time externally, our work on shipments with clinical samples, their carbon footprint, and how we can reduce (and get savings along!)... The title of that Symposium is "Challenges and Solutions of Sample Management": I believe that a challenge (to come) is how we will operate by 2030 in a context of targeted carbon-neutrality (scopes 1, 2 & 3). I will present there one solution we built, which will help a lot in that direction - among others! #environmental #sustainability #shipments #clinical #samples #Novartis
In the upcoming 4th EU Sample Management Symposium on June 20th in Frankfurt, Germany, industry experts will share key insights on the future of sample management. The morning session will be led by Dr. Patrick R. Merz (BASF), Orkun Ozhelvaci (BioNTech) and Neil Gow (UCB Pharma). The afternoon session will be presented by Xavier Briand and Dr. Luc Alexis Leuthold, both from Novartis. For more information on their talks and the Symposium, and to register, visit https://lnkd.in/ezNG6sv7. #SLAS2024 #SampleManagement #Biotech #Pharma
To view or add a comment, sign in
-
Not really. My patent #10,646,535 proves an engineering method which can be used as an intellectual property fence to protect development up botanical new drug. Botanical new drug will be where most of this development occurs. I do agree that cannabis will be somewhat of a novelty soon as we begin REAL research and REAL study of the endocannabinoid system. Why develop with cannabis when you can develop with endocannabinoids? There is no doubt the world changed on 4/30/24...
Cannabis Science and Genetics 🧬 Co-Founder and CSO, S3 🧬 Gene Editing 🧬 BetterCannabisThroughScience Consulting 🧬 Molecular Biologist 🧬 Outdoors Enthusiast
I'm going to continue beating this dead horse. The Cannabis plant is safe from Pharma. Pharma wants single molecules. Novel. Selective. Potent. Patentable. Exhibit A: A new preprint from Swiss pharma giant Roche (and a collaborator from NIH). They describe RNB-61, a new CB2 receptor selective agonist. It is 6000-fold selective over CB1. #BetterCannabisThroughScience Preprint in comments
To view or add a comment, sign in
-
Initially, I saw the reports of #Pfizer's #danuglipron and #SunPharma's #utreglutide and thought we were witnessing another PD-L1 or TNF-inhibitor scenario. I believed they might be late to catch the bus as Novo and Lilly already captured a significant market. However, after reviewing #Roche's press releases and their significant investment in metabolic disorders, I realised the market potential is still unfolding. By the 2030s, this market might be much larger - with nearly 50% of the world's population getting impacted because of #obesity. Roche is making substantial investments in metabolic disorders, boasting a robust pipeline that includes CT-388, CT-996, and CT-868. Their commitment is paying off, with Roche's stock price soaring 10% in the last five days, thanks in part to the positive results of CT-996. The future looks incredibly promising for GLP-1 agonists and metabolic disorder treatments. Exciting Times Ahead for GLP-1 Agonists! #Pharmaceuticals #Biotech #GLP1Agonists #MetabolicDisorders #Roche #Innovation #Healthcare
To view or add a comment, sign in
-
Join PDA Southern California Chapter on August 15 for our Visible Particulates Symposium at BioscienceLA Speakers include Austin Caudle, Xueyuan (Shawn) Wang, Robin Manouchehri, Amgen, Robert Meisenhelter III, Sladjan Maksimovic, Colleen O'Brien Sonia Adamidis New added topic: "Contamination controls for the rubber stoppers" ^ Understanding Visible Particles and Patient Safety ^ Particulate challenges in Autologous Cell Therapy ^ Enforcement Actions in relation to Particles ^ A Study in Improving Sustainability, whilst Reducing Manufacturing Costs ^ Annex 1, Compliant Contamination Control Strategies ^ Achieving Particle Reduction via Supplier Annex 1 Strategies and Innovation in RTF Packaging Register Here: https://lnkd.in/gdAcJFZc https://lnkd.in/gJpdGd7h Amgen Kite Pharma Gerresheimer SCHOTT Redica Systems West Pharmaceutical Services
To view or add a comment, sign in
-
Explore the Agenda for Our December Bioequivalence Training Get insights into general biostudy requirements, in-depth discussions on similarity, comparability, and correlation, and tackle validation challenges. Check out the full agenda for our upcoming bioequivalence training in December to see if it aligns with your goals. Register via the link in the comments! #drugdevelopment #pharma #bioequivalence #IVIVC #onlinetraining
To view or add a comment, sign in
-
High rates of vomiting for CT-388, the dual GLP-1/GIP experimantal drug candidate from Roche blotches the road ahead. 22 mg of the dose of the drug, average weight loss 18.9% at 24 weeks. During the 12 week period, more than 80% patients experienced nausea and 75% vomiting. Not sure if dogs experienced any nausea and vomiting when tested with CT-388 in the preclinical setup.
To view or add a comment, sign in
-
𝐍𝐞𝐰 𝐩𝐫𝐞𝐬𝐬 𝐫𝐞𝐥𝐞𝐚𝐬𝐞🚨 Integral Molecular's latest study in mAbs reveals that up to one-third of antibody-based drugs show off-target binding, a key cause of adverse events and drug failures. Early specificity testing with our 𝐌𝐞𝐦𝐛𝐫𝐚𝐧𝐞 𝐏𝐫𝐨𝐭𝐞𝐨𝐦𝐞 𝐀𝐫𝐫𝐚𝐲™ can help developers de-risk and improve drug safety. 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞: https://lnkd.in/e-A-xKBF #antibody #drugdevelopment #antibodies #biotech #targetbinding
To view or add a comment, sign in
9,266 followers
More from this author
-
The more the merrier? The emergence of new oral antiviral treatments for COVID-19
Lifescience Dynamics Limited 1y -
To bnAb or not to bnAb?... How will bnAbs fit into the HIV treatment paradigm?
Lifescience Dynamics Limited 1y -
Clash of the Titans: ViiV/GSK shares data from head-to-head trial of every-2-month injectable vs Gilead’s once-daily oral for PLWHIV
Lifescience Dynamics Limited 1y